‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics

Aiming To Help Patients Who Fail Auto CAR-Ts

 
• By Andrew McConaghie
  
Precision Biosciences
Precision Biosciences hopes it can be the first to bring an allogeneic CAR-T to market, and prove the value of its gene-editing platform. • Source: Alamy

More from R&D

More from Pink Sheet